Obafemi Awolowo University

Talk to us

This email address is being protected from spambots. You need JavaScript enabled to view it.

Reach out to us: admissionsoffice@oauife.edu.ng | counselling@oauife.edu.ng | transcript@oauife.edu.ng 

OAU Researchers Awarded Patent In Collaborative Research Works

NG/PT/NC/2016/1957 - Medical Electronic Percussion Appliance (MEPA)

INVENTORS: Prof. L. O. Kehinde, Miss. J. O. Utulu, Mr. O. D. Oderhohwo, Dr. O. Ogunlade 

INVENTION:

A design of a Medical Electronic Percussion Appliance (MEPA) has resulted in the award of a patent No. NG/PT/NC/2016/1957.

This is a joint collaborative research between researchers in the Department of Electronic and Electrical Engineering and a researcher in the Department of Physiological Sciences. The Instrumentation research group in this design is headed by Prof. L. O. Kehinde and the other members of this design team are Mr. Joseph UTULU and Miss Ogheneuriri ODERHOHWO. The researcher from the Physiological Sciences is Dr. Oluwadare Ogunlade.

The Medical Electronic Percussion Appliance hereby described and referred to as MEPA consists of an electromechanical assembly that perturbs a patient’s body (in this case, the human chest or abdomen)  and a sound signal monitoring section that tells the kind of percussion note (sound) received based on the properties of the sound that is generated from the percussed area. Fast Fourier Transform (FFT) Library is employed to get the frequency components of the analyzed signal. This received frequency is displayed on a Liquid Crystal Display as well as represented by brightly coloured LEDs. 

This new MEPA device brings with it the advantage of performing percussion, frequency analysis and display of percussion note (sound) in real time, thereby aiding fast and reliable diagnosis which had been absent in earlier designs.

The patent was processed through the OAU’s IPTTO Office located at the former Distance Learning Complex, off road 1, OAU, Ile-Ife. The Office is always ready to assist researchers/inventors process their Intellectual Property Rights (IPRs) resulting from research activities. IPRs are Intellectual Assets that enhance the value of invention for the purpose of commercialization through outright sale, exploitation or licensing of the invention. IP Assets are more relevant for meeting market needs and wealth creation through university-industry linkage, technology transfer and licensing in this knowledge-driven age.

IPTTO can be contacted through This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it. for further information on all issues relating to IPRs (Patent, Copyright, Trademarks, Industrial Designs, and Trade Secret among others)

Read more...

OAU Scientist Discovers New Anti-Cancer Oleanoic Acid Glycoside

INVENTORS: Prof. Joseph A. Aladesanmi, Mr. Ayodeji O. Oriola, Prof. Gilbert Arthur, Dr. Frank Schweizer 

INVENTION:

The invention is in the field of natural products drug discovery, public health and pharmacy. The invention is a discovery of a new anti-cancer oleanolic acid glycoside from the leaf of Massulariaacuminatausing methanethiosulfonate (MTS) cell proliferation assay with Chlorambucil (200 µg/mL) as standard drug. The leaf ethanolic extract demonstrated the highest anti-cancer activity amongst other plant parts and was fractionated into n-hexane, ethylacetate, n-butanol and aqueous fractions. The most active ethylacetate fraction was purified on repeated column chromatography plus preparative thin-layer chromatography (PTLC) which afforded the new compound and was characterized as α-L-rhamnopyranosyl-(1→2)-3-O-α-D-glucopyranosyloleanolic acid.

The compound demonstrated higher anti-cancer activity than the standard drug used. It was cytotoxic against breast (MDA-MB-231, Hs578t and JIMT-1), cervical (HeLa), prostate (PC3 and DU145), and pancreatic (MiaPaCa2) cancer cell lines at 25 µg/mL compared to the standard drug at 200 µg/mL. The mechanism of action of this compound was found to be by apoptosis, which is a lead broad spectrum anticancer compound against prostate, breast, cervical, and pancreatic cancers, hence the patent.

The patent was processed through the OAU’s IPTTO Office located at the former Distance Learning Complex, off road 1, OAU, Ile-Ife. The Office is always ready to assist researchers/inventors process their Intellectual Property Rights (IPRs) resulting from research activities. IPRs are Intellectual Assets that enhance the value of invention for the purpose of commercialization through outright sale, exploitation or licensing of the invention. IP Assets are more relevant for meeting market needs and wealth creation through university-industry linkage, technology transfer and licensing in this knowledge-driven age.

IPTTO can be contacted through This email address is being protected from spambots. You need JavaScript enabled to view it., This email address is being protected from spambots. You need JavaScript enabled to view it. for further information on all issues relating to IPRs (Patent, Copyright, Trademarks, Industrial Designs, and Trade Secret among others)

Read more...
Subscribe to this RSS feed

Talk to us

info@oauife.edu.ng